CA2321165A1 - Antibodies against human cd40 - Google Patents
Antibodies against human cd40 Download PDFInfo
- Publication number
- CA2321165A1 CA2321165A1 CA002321165A CA2321165A CA2321165A1 CA 2321165 A1 CA2321165 A1 CA 2321165A1 CA 002321165 A CA002321165 A CA 002321165A CA 2321165 A CA2321165 A CA 2321165A CA 2321165 A1 CA2321165 A1 CA 2321165A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- variable region
- human
- chain variable
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims description 27
- 150000007523 nucleic acids Chemical class 0.000 claims description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims description 12
- 239000013604 expression vector Substances 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 101150013553 CD40 gene Proteins 0.000 abstract description 84
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract description 82
- 102100032937 CD40 ligand Human genes 0.000 abstract description 41
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 abstract description 40
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 abstract description 39
- 239000000427 antigen Substances 0.000 abstract description 32
- 102000036639 antigens Human genes 0.000 abstract description 32
- 108091007433 antigens Proteins 0.000 abstract description 32
- 230000003993 interaction Effects 0.000 abstract description 25
- 230000001419 dependent effect Effects 0.000 abstract description 14
- 230000028996 humoral immune response Effects 0.000 abstract description 10
- 208000009386 Experimental Arthritis Diseases 0.000 abstract description 9
- 238000002054 transplantation Methods 0.000 abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 241000282693 Cercopithecidae Species 0.000 description 79
- 230000005875 antibody response Effects 0.000 description 63
- 230000027455 binding Effects 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 43
- 210000003719 b-lymphocyte Anatomy 0.000 description 41
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 41
- 239000002953 phosphate buffered saline Substances 0.000 description 41
- 210000002966 serum Anatomy 0.000 description 38
- 150000001413 amino acids Chemical group 0.000 description 26
- 238000012360 testing method Methods 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 22
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 238000002965 ELISA Methods 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 20
- 230000001506 immunosuppresive effect Effects 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 108091034117 Oligonucleotide Proteins 0.000 description 15
- 102000037865 fusion proteins Human genes 0.000 description 15
- 108020001507 fusion proteins Proteins 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 229920001213 Polysorbate 20 Polymers 0.000 description 14
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 14
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 14
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 210000005259 peripheral blood Anatomy 0.000 description 13
- 239000011886 peripheral blood Substances 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 108010058846 Ovalbumin Proteins 0.000 description 12
- 241000288906 Primates Species 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000003053 immunization Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 229940092253 ovalbumin Drugs 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 241001529936 Murinae Species 0.000 description 11
- 230000004927 fusion Effects 0.000 description 11
- 238000010172 mouse model Methods 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 206010062016 Immunosuppression Diseases 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000002163 immunogen Effects 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 230000003389 potentiating effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- 241000283707 Capra Species 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 230000004940 costimulation Effects 0.000 description 7
- 230000000139 costimulatory effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 241000282567 Macaca fascicularis Species 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 230000001052 transient effect Effects 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 108010022394 Threonine synthase Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 102000004419 dihydrofolate reductase Human genes 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 229940125721 immunosuppressive agent Drugs 0.000 description 4
- 238000000099 in vitro assay Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000000503 Collagen Type II Human genes 0.000 description 3
- 108010041390 Collagen Type II Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 101710131437 Gene 39 protein Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- SXXHYAMKYMNIHI-UHFFFAOYSA-N fluoroimino(sulfanylidene)methane Chemical compound FN=C=S SXXHYAMKYMNIHI-UHFFFAOYSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000002825 functional assay Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 210000001322 periplasm Anatomy 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000005546 dideoxynucleotide Substances 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010063916 CD40 Antigens Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 238000011763 DBA/1J (JAX™ mouse strain) Methods 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004551 Interleukin-10 Receptors Human genes 0.000 description 1
- 108010017550 Interleukin-10 Receptors Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010023439 Kidney transplant rejection Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- -1 SRBCs Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000021766 negative regulation of B cell proliferation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/026,291 US6051228A (en) | 1998-02-19 | 1998-02-19 | Antibodies against human CD40 |
| US09/026,291 | 1998-02-19 | ||
| PCT/US1999/002949 WO1999042075A2 (en) | 1998-02-19 | 1999-02-10 | Antibodies against human cd40 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2321165A1 true CA2321165A1 (en) | 1999-08-26 |
Family
ID=21830976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002321165A Abandoned CA2321165A1 (en) | 1998-02-19 | 1999-02-10 | Antibodies against human cd40 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US6051228A (enExample) |
| EP (1) | EP1054692A4 (enExample) |
| JP (1) | JP2002503495A (enExample) |
| KR (1) | KR100564376B1 (enExample) |
| CN (1) | CN1198647C (enExample) |
| AR (1) | AR018101A1 (enExample) |
| AU (1) | AU751064B2 (enExample) |
| BG (1) | BG65010B1 (enExample) |
| BR (1) | BR9908045A (enExample) |
| CA (1) | CA2321165A1 (enExample) |
| CO (1) | CO4830493A1 (enExample) |
| CZ (1) | CZ20003008A3 (enExample) |
| EE (1) | EE200000470A (enExample) |
| GE (1) | GEP20033016B (enExample) |
| HU (1) | HUP0100763A3 (enExample) |
| ID (1) | ID25792A (enExample) |
| IL (2) | IL137294A0 (enExample) |
| LT (1) | LT4837B (enExample) |
| LV (1) | LV12561B (enExample) |
| MY (1) | MY121464A (enExample) |
| NO (1) | NO20004133L (enExample) |
| NZ (1) | NZ505696A (enExample) |
| PE (1) | PE20000268A1 (enExample) |
| PL (1) | PL197143B1 (enExample) |
| RU (1) | RU2220980C2 (enExample) |
| SK (1) | SK12092000A3 (enExample) |
| TR (1) | TR200002405T2 (enExample) |
| TW (1) | TWI226334B (enExample) |
| UA (1) | UA71909C2 (enExample) |
| WO (1) | WO1999042075A2 (enExample) |
| ZA (1) | ZA991307B (enExample) |
Families Citing this family (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US7175847B1 (en) * | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
| US6113898A (en) * | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| US7153508B2 (en) * | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
| WO1998003670A1 (en) * | 1996-07-23 | 1998-01-29 | Tanox Pharma B.V. | Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| EP2039368A3 (en) | 1999-04-30 | 2009-04-01 | La Jolla Institute For Allergy And Immunology | Methods for preventing reactivation of latent virus and controlling virus replication |
| AU777970C (en) | 1999-05-07 | 2006-08-17 | F. Hoffman-La Roche Ag | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
| US7829064B2 (en) * | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
| US8119101B2 (en) * | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
| US8383081B2 (en) * | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
| US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| HK1046635B (en) * | 1999-06-09 | 2009-10-09 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| WO2001013945A1 (en) * | 1999-08-23 | 2001-03-01 | Biocrystal Ltd. | Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis |
| EP1839674A1 (en) * | 1999-10-04 | 2007-10-03 | Novartis Vaccines and Diagnostics, Inc. | CD40 antagonist for treating psoriasis |
| JP2003510371A (ja) * | 1999-10-04 | 2003-03-18 | カイロン コーポレイション | 乾癬を処置するためのｃｄ４０アンタゴニスト |
| US6849425B1 (en) * | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| AU1590201A (en) * | 1999-11-09 | 2001-06-06 | Chiron Corporation | Compositions and methods for treating autoimmune diseases and transplant rejections |
| GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| GB0006398D0 (en) * | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| CN1450912A (zh) * | 2000-04-19 | 2003-10-22 | 泰诺士公司 | 用于治疗牛皮癣和其它炎性皮肤病的cd40拮抗剂 |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| WO2002022212A2 (en) * | 2000-09-18 | 2002-03-21 | Idec Pharmaceuticals Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| CA2440831C (en) * | 2001-04-02 | 2013-05-28 | Genentech, Inc. | Combination therapy using cd40 and cd20 ligands |
| ATE374214T1 (de) * | 2001-04-27 | 2007-10-15 | Kirin Brewery | Monoklonaler anti-cd-40-antikörper |
| WO2003024480A2 (en) * | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| JP2005510570A (ja) * | 2001-11-26 | 2005-04-21 | カイロン コーポレイション | 多発性硬化症処置のためのアンタゴニスト抗ｃｄ４０モノクローナル抗体療法 |
| EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| EP1483294B2 (en) * | 2002-03-01 | 2019-10-30 | Immunomedics, Inc. | Internalizing anti-cd74 antibodies and methods of use |
| US7495090B2 (en) * | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| WO2004052398A1 (en) * | 2002-12-09 | 2004-06-24 | Tolerrx, Inc. | Inducing tolerance in primates |
| US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| EP2248830A1 (en) * | 2003-11-04 | 2010-11-10 | Novartis Vaccines and Diagnostics, Inc. | Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection |
| US7312320B2 (en) * | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
| US7674884B2 (en) * | 2003-12-10 | 2010-03-09 | Novimmune S.A. | Neutralizing antibodies and methods of use thereof |
| US8883160B2 (en) * | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| US9550838B2 (en) | 2004-02-13 | 2017-01-24 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| KR20060132006A (ko) | 2004-03-23 | 2006-12-20 | 비오겐 아이덱 엠에이 아이엔씨. | 수용체 커플링제 및 이의 치료적 용도 |
| AU2004324464A1 (en) * | 2004-10-22 | 2006-05-04 | Applied Molecular Evolution, Inc. | Methods of optimizing antibody variable region binding affinity |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
| US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
| PT1868635T (pt) * | 2005-04-06 | 2017-07-27 | Bristol Myers Squibb Co | Métodos para tratar distúrbios imunes associados a transplantação de enxerto com moléculas mutantes solúveis de ctla4 |
| US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
| HRP20130852T1 (en) * | 2005-05-18 | 2013-10-25 | Novartis Ag | Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component |
| ES2354865T3 (es) | 2005-05-26 | 2011-03-18 | Seattle Genetics, Inc. | Anticuerpos anti-cd40 humanizados y métodos para utilizarlos. |
| US7668387B2 (en) * | 2005-06-20 | 2010-02-23 | Intel Corporation | Selective local transient improvement and peaking for video sharpness enhancement |
| SG10201403526YA (en) * | 2005-07-25 | 2014-10-30 | Emergent Product Dev Seattle | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| US20070202549A1 (en) * | 2005-09-14 | 2007-08-30 | University Of Pittsburgh | Assessing risk of cerebrovascular thrombosis by measuring C4d on platelets |
| WO2007033369A2 (en) * | 2005-09-14 | 2007-03-22 | University Of Pittsburgh | Assessing risk of cerebrovascular thrombosis by measuring c4d on platelets |
| US20080131914A1 (en) * | 2005-09-14 | 2008-06-05 | Ahearn Joseph M | Assessing risk of cerebrovascular thrombosis by measuring c4d |
| JP2009517339A (ja) | 2005-11-01 | 2009-04-30 | ノバルティス アーゲー | 抗ｃｄ４０抗体の使用 |
| NZ571757A (en) | 2006-04-21 | 2012-01-12 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer |
| CN101479375B (zh) | 2006-05-03 | 2016-03-30 | 科罗拉多州立大学董事会 | Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其作为增强细胞免疫的治疗剂的用途 |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| AU2007281737B2 (en) * | 2006-08-04 | 2013-09-19 | Baxter Healthcare S.A. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
| AR067543A1 (es) * | 2007-07-16 | 2009-10-14 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso |
| CN106432496B (zh) | 2007-07-16 | 2020-02-07 | 健泰科生物技术公司 | 抗cd79b抗体和免疫偶联物及使用方法 |
| EP2247620B1 (en) | 2008-01-31 | 2016-05-18 | Genentech, Inc. | Anti-cd79b antibodies and immunoconjugates and methods of use |
| AU2010222929B2 (en) * | 2008-07-16 | 2013-07-25 | Baylor Research Institute | Antigen presenting cell targeted anti-viral vaccines |
| CA2754906C (en) | 2009-03-10 | 2021-02-09 | Baylor Research Institute | Antigen presenting cell targeted fusion proteins comprising a linker for increased stability |
| WO2011085354A1 (en) * | 2010-01-11 | 2011-07-14 | Center For Molecular Medicine And Immunology | Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma |
| RS57114B1 (sr) | 2010-03-31 | 2018-06-29 | Boehringer Ingelheim Int | Anti-cd40 antitela |
| ES2616010T3 (es) * | 2010-05-14 | 2017-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Anticuerpos monoclonales humanizados y quiméricos a CD47 |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| PL2683406T3 (pl) | 2011-03-11 | 2019-11-29 | Beth Israel Deaconess Medical Ct Inc | Przeciwciała anty-cd40 i ich zastosowania |
| EP2699601B1 (en) | 2011-04-21 | 2018-01-17 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize cd40 |
| AU2012249454B2 (en) | 2011-04-29 | 2016-03-24 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
| GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| US9192664B2 (en) | 2011-12-05 | 2015-11-24 | Immunomedics, Inc. | Therapeutic use of anti-CD22 antibodies for inducing trogocytosis |
| US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
| US9676861B2 (en) | 2012-10-30 | 2017-06-13 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
| US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
| ES2819573T3 (es) | 2012-12-13 | 2021-04-16 | Immunomedics Inc | Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A |
| US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
| US12310958B2 (en) | 2012-12-13 | 2025-05-27 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US20240148873A1 (en) | 2012-12-13 | 2024-05-09 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
| US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
| US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| BR112015013444B1 (pt) | 2012-12-13 | 2022-11-01 | Immunomedics, Inc | Uso de um imunoconjugado |
| US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| AU2015204503B2 (en) | 2014-01-13 | 2020-07-09 | Baylor Research Institute | Novel vaccines against HPV and HPV-related diseases |
| CN106029098A (zh) | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | 人源化rfb4抗cd22抗体 |
| WO2015134988A1 (en) | 2014-03-07 | 2015-09-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| CA2957146A1 (en) | 2014-08-12 | 2016-02-18 | Alligator Bioscience Ab | Combination therapies with anti cd40 antibodies |
| EP3194442A4 (en) * | 2014-09-16 | 2018-05-23 | UBI IP Holdings | Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition |
| SI3262071T1 (sl) | 2014-09-23 | 2020-07-31 | F. Hoffmann-La Roche Ag | Način uporabe imunokonjugatov proti CD79b |
| CN107073118B (zh) | 2014-10-29 | 2022-03-01 | 西雅图基因公司 | 非岩藻糖基化抗cd40抗体的剂量和给药 |
| AU2015360502A1 (en) | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| AU2016252771B2 (en) | 2015-04-22 | 2021-12-16 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
| JP6518917B2 (ja) | 2015-05-29 | 2019-05-29 | アッヴィ・インコーポレイテッド | 抗ｃｄ４０抗体およびその使用 |
| US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| SI3307322T1 (sl) | 2015-09-04 | 2021-08-31 | Primatope Therapeutics Inc. | Humanizirana protitelesa proti CD40 in njihove uporabe |
| EP3355921A4 (en) | 2015-09-30 | 2019-05-22 | Janssen Biotech, Inc. | ANTAGONIST ANTIBODIES SPECIFICALLY BINDING TO HUMAN CD40 AND METHODS OF USE |
| EP3413914A4 (en) | 2016-02-10 | 2019-10-16 | Immunomedics, Inc. | COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) TO OVERCOME THE RESISTANCE TO SN-38 IN TROP-2-EXPRESSIVE CANCER |
| CN108778301A (zh) | 2016-03-10 | 2018-11-09 | 永恒生物科技股份有限公司 | 通过联合疗法来治疗实体瘤或淋巴瘤的方法 |
| AU2017257254B2 (en) | 2016-04-27 | 2022-02-24 | Immunomedics, Inc. | Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
| CA3026474A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| JP2020512314A (ja) | 2017-03-27 | 2020-04-23 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | サシツズマブゴビテカンとＲＡＤ５１阻害剤を用いたＴｒｏｐ−２発現トリプルネガティブ乳癌の治療 |
| EP3606964A4 (en) | 2017-04-03 | 2020-12-09 | Immunomedics, Inc. | SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY |
| US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
| CN112566933B (zh) | 2018-07-20 | 2023-07-14 | 祐和医药科技(北京)有限公司 | 抗cd40抗体及其用途 |
| US20200190163A1 (en) * | 2018-10-26 | 2020-06-18 | Lijun Wu | Humanized bcma-car-t cells |
| US12297265B2 (en) | 2018-12-28 | 2025-05-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody and use thereof |
| CN111454363B (zh) * | 2019-03-04 | 2021-03-02 | 北京天广实生物技术股份有限公司 | Cd40抗体及其用途 |
| CN117683133A (zh) * | 2019-09-03 | 2024-03-12 | 百奥泰生物制药股份有限公司 | 一种抗tigit免疫抑制剂及应用 |
| CN113563473A (zh) | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| CN111763259B (zh) * | 2020-09-03 | 2020-12-15 | 北京百奥赛图基因生物技术有限公司 | 抗cd40抗体及其用途 |
| WO2023025248A1 (zh) | 2021-08-26 | 2023-03-02 | 映恩生物制药（苏州）有限公司 | 一种甾体化合物及其缀合物 |
| CN118234749A (zh) * | 2021-09-17 | 2024-06-21 | 诺华股份有限公司 | 用于预防异种移植中的移植物排斥的方法 |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| US20240190978A1 (en) | 2022-11-15 | 2024-06-13 | CSBioAsset LLC | Compositions and methods for immunomodulatory bifunctional fusion molecules |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU3226593A (en) * | 1991-11-26 | 1993-06-28 | Regents Of The University Of California, The | Cloning vectors for expressing pcr generated variable regions as complete heavy and/or light chain(s) |
| US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5683693A (en) * | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
| ATE226641T1 (de) * | 1995-04-08 | 2002-11-15 | Lg Chemical Ltd | Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| KR20000034847A (ko) * | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
-
1998
- 1998-02-19 US US09/026,291 patent/US6051228A/en not_active Expired - Lifetime
-
1999
- 1999-01-30 MY MYPI99000336A patent/MY121464A/en unknown
- 1999-02-10 RU RU2000124084/13A patent/RU2220980C2/ru not_active IP Right Cessation
- 1999-02-10 CZ CZ20003008A patent/CZ20003008A3/cs unknown
- 1999-02-10 AU AU26716/99A patent/AU751064B2/en not_active Ceased
- 1999-02-10 IL IL13729499A patent/IL137294A0/xx active IP Right Grant
- 1999-02-10 CA CA002321165A patent/CA2321165A1/en not_active Abandoned
- 1999-02-10 HU HU0100763A patent/HUP0100763A3/hu unknown
- 1999-02-10 ID IDW20001577A patent/ID25792A/id unknown
- 1999-02-10 WO PCT/US1999/002949 patent/WO1999042075A2/en not_active Ceased
- 1999-02-10 US US09/247,352 patent/US6312693B1/en not_active Expired - Lifetime
- 1999-02-10 CN CNB998031496A patent/CN1198647C/zh not_active Expired - Fee Related
- 1999-02-10 EE EEP200000470A patent/EE200000470A/xx unknown
- 1999-02-10 PL PL342668A patent/PL197143B1/pl unknown
- 1999-02-10 SK SK1209-2000A patent/SK12092000A3/sk unknown
- 1999-02-10 BR BR9908045-1A patent/BR9908045A/pt not_active Application Discontinuation
- 1999-02-10 TR TR2000/02405T patent/TR200002405T2/xx unknown
- 1999-02-10 EP EP99906915A patent/EP1054692A4/en not_active Withdrawn
- 1999-02-10 JP JP2000532092A patent/JP2002503495A/ja not_active Withdrawn
- 1999-02-10 GE GEAP19995505A patent/GEP20033016B/en unknown
- 1999-02-10 NZ NZ505696A patent/NZ505696A/en unknown
- 1999-02-10 KR KR1020007009046A patent/KR100564376B1/ko not_active Expired - Fee Related
- 1999-02-18 CO CO99010014A patent/CO4830493A1/es unknown
- 1999-02-18 ZA ZA9901307A patent/ZA991307B/xx unknown
- 1999-02-19 PE PE1999000146A patent/PE20000268A1/es not_active Application Discontinuation
- 1999-02-22 TW TW088102330A patent/TWI226334B/zh not_active IP Right Cessation
- 1999-02-23 AR ARP990100704A patent/AR018101A1/es active IP Right Grant
- 1999-10-02 UA UA2000095347A patent/UA71909C2/uk unknown
- 1999-12-17 US US09/466,635 patent/US6413514B1/en not_active Expired - Lifetime
-
2000
- 2000-07-13 IL IL137294A patent/IL137294A/en unknown
- 2000-08-17 LT LT2000080A patent/LT4837B/lt not_active IP Right Cessation
- 2000-08-18 NO NO20004133A patent/NO20004133L/no not_active Application Discontinuation
- 2000-08-23 LV LVP-00-107A patent/LV12561B/en unknown
- 2000-09-19 BG BG104778A patent/BG65010B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU751064B2 (en) | Antibodies against human CD40 | |
| US6887673B2 (en) | Humanized antibodies against human 4-1BB | |
| KR101276596B1 (ko) | 면역억제 특성을 가진 인간화 항-ｃｄ4 항체 | |
| CN101589062B (zh) | 与胰高血糖素受体抗体相关的组合物和方法 | |
| KR102003754B1 (ko) | Pd-l1 항체와 이를 이용한 치료 및 진단 | |
| DK2364729T6 (en) | IL-17 antagonistic antibodies | |
| CA2681530C (en) | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 | |
| CN101321783B (zh) | 人抗-b7rp1中和抗体 | |
| KR102687014B1 (ko) | 인간화된 항-pd-1 항체 및 이의 용도 | |
| US20170267771A1 (en) | Agonistic antibody to cd27 | |
| JP6794448B2 (ja) | 抗体サイトカイングラフト組成物および免疫調節のための使用方法 | |
| US20070286858A1 (en) | Methods and Compositions for Antagonism of RAGE | |
| TWI482630B (zh) | 抗人類ｔｗｅａｋ抗體及其用途 | |
| JP2019519223A (ja) | 免疫調節タンパク質及び腫瘍抗原に結合する二重特異性結合タンパク質 | |
| SG193805A1 (en) | Compositions and methods of use for therapeutic antibodies | |
| RS20070027A (sr) | Antitela anti-cd154 | |
| WO2023061063A1 (zh) | 靶向cd70的抗体及其制备和用途 | |
| PL207133B1 (pl) | Cząsteczka wiążąca ludzkie monocytowe białko chemotaktyczne (MCP-1), konstrukt DNA, wektor ekspresyjny, kompozycja farmaceutyczna, sposób produkcji cząsteczki wiążącej MCP-1 oraz jej zastosowanie | |
| US20100303808A1 (en) | Humanized anti-cd20 antibodies and methods of use | |
| KR102648583B1 (ko) | 인간 및 원숭이 cd38 항원에 특이적으로 결합하는 단일클론항체 및 이의 제조방법과 용도 | |
| JP2024024118A (ja) | 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体 | |
| HUP0400697A2 (hu) | Elcsendesített anti-CD28 ellenanyagok és használatuk | |
| KR20160010391A (ko) | Cd20 및 cd95에 결합하는 재조합 이중특이성 항체 | |
| KR20230034960A (ko) | Lag3에 결합하는 항체 및 그 용도 | |
| KR20230010691A (ko) | St2 항원 결합 단백질 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |